B+
Overall grade
B+
Financial quality
The sleeper story is Quest legitimizing Shield with commercial payers and health systems that Guardant couldn't crack alone-this isn't just distribution, it's institutional validation that could unlock the under-65 commercial market they've been circling. The obvious headline is 48% revenue growth, but what matters more is G360 Liquid sustaining 30% volume growth in year 10 while holding $3K+ ASPs, proving Smart Apps create real clinical value, not just feature bloat. The binding constraint isn't demand-it's commercial infrastructure for Shield and reimbursement expansion for Reveal therapy monitoring. Management's most revealing quote: 'Quest is already opening doors for us in health systems and physician practices where we did not previously have a strong direct presence.' My view changes if Quest co-promotion doesn't drive measurable volume uplift by Q3 or if ACS guidelines get pushed beyond 2026.
The 30-second version
- Quest partnership is opening payer doors they couldn't crack alone
- G360 Liquid at 30% volume growth after 10 years suggests pricing power intact
- Reveal therapy monitoring launch buried the lede on longitudinal testing
What changed this quarter
| Metric | Prior | This quarter |
|---|---|---|
| Total Revenue | $281M (39% YoY) | $302M (48% YoY) |
| Oncology Revenue | $190M (30% YoY) | $205M (36% YoY) |
| Oncology Test Volumes | 79K (38% YoY) | 86K (47% YoY) |
| G360 Liquid Volume Growth | ~30% YoY | 30% YoY |
| Reveal Volume Growth | Fastest-growing | >100% YoY |
| Shield Revenue | $35M (38K tests) | $42M (44K tests) |
| Shield ASP | ~$850 | Not disclosed but higher YoY |
| Biopharma Revenue | $54M (9% YoY) | $53M (17% YoY) |
Accountability tracked
8 new promises made4 narrative shifts flagged6 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →